Resolutions at the Annual General Meeting in Biotage AB on April 29, 2010

Resolutions at the Annual General Meeting in Biotage AB on April 29, 2010

At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April
29, 2010, the following resolutions were passed, among others.

Appropriation of the company's result

The General Meeting resolved a dividend of SEK 0.20 per share, which in
aggregate is a dividend in the amount of no higher than SEK 17,697,264. 
Record date for dividend was resolved to be Tuesday, 4 May 2010. 

Board of Directors

The General Meeting resolved that the board should be composed of six board
members (with no deputy board members).
The General Meeting resolved to re-elect Ove Mattsson, Thomas Eklund, Staffan
Lindstrand and Per-Olof Eriksson as Board members. The General Meeting resolved
to elect Eva-Lotta Kraft and Anders Walldov as new Board members. The General
Meeting resolved to appoint Ove Mattsson Chairman of the Board. 

The General Meeting resolved that a fee of SEK 1,025,000 shall be paid to the
Board of Directors for the period up to and including the Annual General Meeting
2010 to be distributed as follows: the Chairman shall receive SEK 400,000 and
each of the other Board members elected by the General Meeting who are not
employed by the company shall receive SEK 125,000. In addition to that, a fee
shall be paid to the members of the Auditing Committee of an aggregate of not
more than SEK 100,000, whereof the Chairman shall receive SEK 50,000 and the two
other members SEK 25,000 each.

Nomination Committee

The General Meeting resolved that the Chairman of the Board of Directors shall
be appointed as member of the Nomination Committee and shall be instructed to
appoint, in consultation with the (by voting rights) major shareholders of the
company as per September 1, 2010, another three members. The names of such
members shall be published no later than six months before the Annual General
Meeting 2011. The Nomination Committee shall appoint one of the members to be
the Chairman of the Committee. The Chairman of the Board may not be appointed
Chairman of the Nomination Committee.

The Nomination Committee shall, before the Annual General Meeting 2011, prepare
proposals for the election of Chairman and other members of the Board of
Directors, the election of Chairman of the Annual General Meeting, the
determination of fees and matters pertaining thereto.

Resolution on guidelines for compensation for the executive management

The General Meeting resolved to adopt guidelines for compensation for the
executive management in accordance with the proposal by the Board of Directors.

Authorization for the Board of Directors to issue shares and/or convertibles

The General Meeting resolved to authorize the Board to issue shares and/or
convertibles with or without deviation from the shareholders' pre-emption
rights. The Board of Directors shall have the right to resolve that the shares
and/or the convertibles shall be paid in kind or otherwise be subject to
conditions referred to in Chapter 2 Section 5 second paragraph 1-3 and 5 of the
Swedish Companies Act or that the shares and/or the convertibles shall be
subscribed for with a right of set-off. The Board's resolutions may result in an
increase of the number of shares in the company by not more than 8,800,000
shares in total. 

Authorization for the board of directors to acquire and transfer own shares 

The General Meeting resolved to authorize the board of directors to acquire and
transfer own shares on NASDAQ OMX Stockholm substantially in accordance with
following:
1. The authorisation may be utilised on one or more occasions, however not
longer than until the 2011 annual general meeting. 
2. The company may purchase at the most so many shares that the company's
holding of own shares after the purchase amounts to a maximum of one-tenth of
all the shares in the company.
3. Acquisitions and transfers of shares may only take place at a price within
the price interval at any time recorded on the NASDAQ OMX Stockholm, and this
shall refer to the interval between the highest buying price and the lowest
selling price.

Contact:	
Torben Jörgensen, President and CEO	
Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical
chemistry and medicinal chemistry. The customers include the world's largest
pharmaceutical and biotech companies, and leading academic institutes. The
company is headquartered in Uppsala and has subsidiaries in the US, UK and
Japan. Biotage has 245 employees and had sales of 394.1 MSEK in 2009. Biotage is
listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website:
www.biotage.com